Close
Close

Cognitive Dysfunction in MS: Using Altered Brain Oscillation to Link Molecular Mechanisms With Clinical Outcomes

Disease Information

Descriptive Information
Brief Title † Cognitive Dysfunction in MS: Using Altered Brain Oscillation to Link Molecular Mechanisms With Clinical Outcomes
Official Title † Cognitive Dysfunction in MS: Using Altered Brain Oscillation to Link Molecular Mechanisms With Clinical Outcomes
Brief Summary Up to 65% of patients with multiple sclerosis (MS) experience cognitive dysfunction. Diminution of mental capacity has a pervasive and profound impact on their quality of life. Subtle changes in white matter predict cognitive changes in these patients but how this disrupts brain function remains unclear. Development of effective therapeutics to restore normal cognition hinges on elucidating these functional changes. The investigators seek to uncover the patho-physiological basis for cognitive decline in MS. The investigators hypothesize that cognitive decline originates from disrupted gamma oscillations and that gamma oscillations are disrupted by molecular changes triggered by demyelination.
Detailed Description
Study Phase N/A
Study Type † Observational
Study Design †
Primary Outcome Measure † Neuronal responses during simple and choice reaction time tasks
Secondary Outcome Measure †
Condition † Pediatric Multiple Sclerosis
Intervention †
Study Arms / Comparison Groups 7 pediatric-onset multiple sclerosis 7 non-patient healthy volunteers
Publications *

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information
Recruitment Status †
Estimated Enrollment † 14
Start Date † June 2017
Completion Date June 2018
Primary Completion Date June 2018
Eligibility Criteria † Inclusion Criteria (*applicable to controls): 1. Must be between 6 and 17 years and 11 months of age*; 2. Have a diagnosis of MS according to the revised McDonald diagnostic criteria and/or International Pediatric MS Study Group criteria; 3. Has English language knowledge at the level needed to complete clinical questionnaires (4th grade level).* Exclusion Criteria (*applicable to controls): 1. Neurological comorbidity.*; 2. Relapses or requires treatment with steroids within 30 days from enrollment; 3. Is pregnant at the time of enrollment.*; 4. Has any metal parts in their body (i.e. Cochlear (ear) implant, metal braces (dental fillings are o.k.).*; 5. Is younger than 6 years of age.*; 6. Is older than 18 years of age.*; 7. Has prior history of traumatic brain injury, neurological disorder, cerebral palsy, developmental delay or learning disability.*; 8. Requires sedation for brain scanning.*; 9. Is claustrophobic, as brain scanning requires children to enter a tunnel in the MRI machine.*
Gender All
Ages 6 Years - 18 Years
Accepts Healthy Volunteers Accepts Healthy Volunteers
Contacts †† Ann E. Yeh, 416-813-7654, ann.yeh@sickkids.ca
Location Countries † Canada
Administrative Information
NCT ID † NCT03066752
Organization ID 1000054117
Secondary IDs ††
Responsible Party Principal Investigator
Study Sponsor † The Hospital for Sick Children
Collaborators ††
Investigators † : ,
Information Provided By
Verification Date February 2017
First Received Date † January 3, 2017
Last Updated Date February 23, 2017
† Required WHO trial registration data element.
†† WHO trial registration data element that is required only if it exists.
Find a Clinical Trial
Free Newsletter